SLC30A4-AS1: A Potential Drug Target and Biomarker (G105376714)

Target Name: SLC30A4-AS1

NCBI ID: G105376714

Other Name(s): Uncharacterized protein LOC105376714 | LOC105376714 | SLC30A4 antisense RNA 1

SLC30A4-AS1: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 30 (SLC30) is a transmembrane protein that plays a crucial role in the efficient transport of sodium and glucose across cell membranes. The SLC30 gene has four splice variants, SLC30A4-AS1, SLC30A4-AS2, SLC30A4-AS3, and SLC30A4-AS4. SLC30A4-AS1 is the most abundant isoform and is widely expressed in various tissues and organs, including brain, heart, skeletal muscles, and red blood cells. This protein has been implicated in various physiological processes, including cell signaling, neurodegeneration, and diseases such as diabetes. Therefore, understanding the functions of SLC30A4-AS1 and its potential as a drug target or biomarker is of great interest.

Properties and Characterization

SLC30A4-AS1 is a 21.1 kDa protein that consists of 114 amino acid residues. It has a single transmembrane region and a N-terminal cytoplasmic region. The protein is highly conserved, with a calculated pI of 6.9 and a hydration state of 16%. SLC30A4-AS1 can form a monomeric structure in solution and is soluble in SDS-PAGE samples with a range of pHs.

SLC30A4-AS1 has been shown to play a critical role in various physiological processes. For example, SLC30A4-AS1 has been shown to regulate the uptake of glucose by GLUT1, a glucose transporter located in the endosomal system. GLUT1 is known to play a crucial role in the delivery of glucose to the brain for energy metabolism and is also involved in the development and progression of neurodegenerative diseases. Therefore, modulating SLC30A4-AS1 activity may provide new insights into the pathophysiology of these diseases and may be a potential therapeutic approach.

In addition to its role in GLUT1 function, SLC30A4-AS1 has also been shown to play a critical role in cell signaling. SLC30A4-AS1 has been shown to interact with various intracellular signaling pathways, including the NF-kappa pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These interactions may regulate various cellular processes, including cell growth, differentiation, and inflammation. Therefore, modulating SLC30A4-AS1 activity may provide new insights into the mechanisms underlying these signaling pathways and may be a potential therapeutic approach for diseases associated with these pathways.

Drug Target Potential

SLC30A4-AS1 has been identified as a potential drug target due to its unique structure and its involvement in various physiological processes. Several studies have suggested that modulating SLC30A4-AS1 activity may be a promising approach for treating various diseases.

1. Diabetes: SLC30A4-AS1 has been shown to regulate the uptake of glucose by GLUT1, which is involved in the delivery of glucose to the brain for energy metabolism. Therefore, modulating SLC30A4-AS1 activity may be a promising approach for treating diabetes. Several studies have shown that GLUT1 is overexpressed in various tissues of diabetes patients, including the brain. Therefore, targeting SLC30A4-AS1 with drugs that modulate its activity may be a potential therapeutic approach for diabetes.

2. Neurodegenerative Diseases: SLC30A4-AS1 has been shown to play a critical role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, modulating SLC30A4-AS1 activity

Protein Name: SLC30A4 Antisense RNA 1

More Common Targets